179 related articles for article (PubMed ID: 38358974)
21. Potential inhibitors of RPS6KB2 and NRF2 in head and neck squamous cell carcinoma.
Madhukar G; Subbarao N
J Biomol Struct Dyn; 2024; 42(4):1875-1900. PubMed ID: 37160694
[TBL] [Abstract][Full Text] [Related]
22. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
Elife; 2017 Oct; 6():. PubMed ID: 28967863
[TBL] [Abstract][Full Text] [Related]
23. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation.
Gong M; Li Y; Ye X; Zhang L; Wang Z; Xu X; Shen Y; Zheng C
Cell Commun Signal; 2020 Jun; 18(1):98. PubMed ID: 32576270
[TBL] [Abstract][Full Text] [Related]
24. NRF2-Driven
Tian Y; Liu Q; Yu S; Chu Q; Chen Y; Wu K; Wang L
Mol Cancer Res; 2020 Oct; 18(10):1465-1476. PubMed ID: 32571982
[TBL] [Abstract][Full Text] [Related]
25. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
[TBL] [Abstract][Full Text] [Related]
26. Glioma tumor suppressor candidate region gene 1 (GLTSCR1) and its paralog GLTSCR1-like form SWI/SNF chromatin remodeling subcomplexes.
Alpsoy A; Dykhuizen EC
J Biol Chem; 2018 Mar; 293(11):3892-3903. PubMed ID: 29374058
[TBL] [Abstract][Full Text] [Related]
27. Disruption of KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex components by multiple genetic mechanisms: Association with poor prognosis in head and neck cancer.
Martinez VD; Vucic EA; Thu KL; Pikor LA; Lam S; Lam WL
Head Neck; 2015 May; 37(5):727-34. PubMed ID: 24596130
[TBL] [Abstract][Full Text] [Related]
28. SWI/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability.
Watanabe R; Ui A; Kanno S; Ogiwara H; Nagase T; Kohno T; Yasui A
Cancer Res; 2014 May; 74(9):2465-75. PubMed ID: 24788099
[TBL] [Abstract][Full Text] [Related]
29. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
Roh JL; Kim EH; Jang H; Shin D
Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
[TBL] [Abstract][Full Text] [Related]
30. New insights into the mechanism of Keap1-Nrf2 interaction based on cancer-associated mutations.
Cheng L; Wang H; Li S; Liu Z; Wang C
Life Sci; 2021 Oct; 282():119791. PubMed ID: 34229009
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic mutations in KEAP1 disturbing inhibitory Nrf2-Keap1 interaction: Activation of antioxidative pathway in papillary thyroid carcinoma.
Danilovic DLS; de Mello ES; Frazzato EST; Wakamatsu A; de Lima Jorge AA; Hoff AO; Marui S
Head Neck; 2018 Jun; 40(6):1271-1278. PubMed ID: 29469959
[TBL] [Abstract][Full Text] [Related]
32. Genome-Wide Transcriptional Regulation Mediated by Biochemically Distinct SWI/SNF Complexes.
Raab JR; Resnick S; Magnuson T
PLoS Genet; 2015 Dec; 11(12):e1005748. PubMed ID: 26716708
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
[TBL] [Abstract][Full Text] [Related]
34. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
35. Respiratory syncytial virus induces NRF2 degradation through a promyelocytic leukemia protein - ring finger protein 4 dependent pathway.
Komaravelli N; Ansar M; Garofalo RP; Casola A
Free Radic Biol Med; 2017 Dec; 113():494-504. PubMed ID: 29107745
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Targeting of the NRF2 Signaling Pathway in Cancer.
Telkoparan-Akillilar P; Panieri E; Cevik D; Suzen S; Saso L
Molecules; 2021 Mar; 26(5):. PubMed ID: 33808001
[TBL] [Abstract][Full Text] [Related]
37. BAFfling pathologies: Alterations of BAF complexes in cancer.
Arnaud O; Le Loarer F; Tirode F
Cancer Lett; 2018 Apr; 419():266-279. PubMed ID: 29374542
[TBL] [Abstract][Full Text] [Related]
38. ARID1A mutations in endometriosis-associated ovarian carcinomas.
Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
[TBL] [Abstract][Full Text] [Related]
39. NF-κB and Keap1 Interaction Represses Nrf2-Mediated Antioxidant Response in Rabbit Hemorrhagic Disease Virus Infection.
Hu B; Wei H; Song Y; Chen M; Fan Z; Qiu R; Zhu W; Xu W; Wang F
J Virol; 2020 May; 94(10):. PubMed ID: 32161178
[TBL] [Abstract][Full Text] [Related]
40. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
